New hope for men with early spread prostate cancer: shorter drug course may boost quality of life
NCT ID NCT05404139
First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times
Summary
This study looks at men whose prostate cancer has spread to a few spots in the body (oligometastatic). It compares standard radiation and hormone therapy alone versus adding the drug abiraterone for 8-9 months. The goal is to see if the extra drug improves quality of life and delays cancer progression. About 132 men will take part, and they will be followed for up to 5 years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Princess Margaret Cancer Center
RECRUITINGToronto, Ontario, M5G 2M9, Canada
-
Sunnybrook Research Institute
ACTIVE_NOT_RECRUITINGToronto, Ontartio, M4N 3M5, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Can a blood filtering technique reveal more about prostate cancer spread?
- Can a vaccine plus immune booster tackle resistant prostate cancer?
- Can a smart drug deliver a toxic payload to prostate cancer cells?
- Can a blast of testosterone shrink hard-to-treat prostate cancer?
- A PET scan and a blood test may predict which men with advanced prostate cancer will benefit from targeted therapy